No Data
No Data
JOINN Laboratories Announces Board Roles and Leadership
JOINN Laboratories Redirects Funds to Boost U.S. Operations
JOINN Laboratories Partners With Staidson for 2025 R&D Services
Joinn Laboratories (06127.HK) has entered into a research and development service agreement with Staidson for the year 2025.
On December 20, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 20, 2024, the company entered into a 2025 research and development service framework agreement with Staidson, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases according to the 2025 Staidson research and development service framework agreement.
Express News | Joinn Laboratories China - Zuo Conglin Resigned as Executive Director
Joinn Laboratories (603127.SH): plans to invest no more than 8 million yuan to establish the first phase of the Peking Fund.
On December 20, Gelonghui reported that Joinn Laboratories (603127.SH) announced that the company or its designated subsidiaries intend to sign a partnership agreement (hereinafter referred to as the "Partnership Agreement") with Peking Chongde Yingsheng Investment Management Co., Ltd. (hereinafter referred to as "Chongde Yingsheng"), Peking Huizhi Fu Technology Development Co., Ltd. (hereinafter referred to as "Huizhi Fu"), and Peking Guochao Super-Group Intelligent Technology Co., Ltd. (hereinafter referred to as "Guochao Super-Group") to participate in the investment in the Northern Brain Phase I Fund (hereinafter referred to as "this Fund"). This Fund plans to focus on brain science and mainly invest in areas such as the diagnosis and treatment of a new generation of neurological diseases.
No Data